RU2018119112A - Композиции и способы на основе dac hyp - Google Patents
Композиции и способы на основе dac hyp Download PDFInfo
- Publication number
- RU2018119112A RU2018119112A RU2018119112A RU2018119112A RU2018119112A RU 2018119112 A RU2018119112 A RU 2018119112A RU 2018119112 A RU2018119112 A RU 2018119112A RU 2018119112 A RU2018119112 A RU 2018119112A RU 2018119112 A RU2018119112 A RU 2018119112A
- Authority
- RU
- Russia
- Prior art keywords
- daclizumab
- composition
- cell
- dac hyp
- day
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 75
- 238000000034 method Methods 0.000 title claims 60
- 229960002806 daclizumab Drugs 0.000 claims 69
- 210000004027 cell Anatomy 0.000 claims 32
- 238000013103 analytical ultracentrifugation Methods 0.000 claims 16
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 14
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 14
- 102000001708 Protein Isoforms Human genes 0.000 claims 11
- 108010029485 Protein Isoforms Proteins 0.000 claims 11
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 102000003996 Interferon-beta Human genes 0.000 claims 6
- 108090000467 Interferon-beta Proteins 0.000 claims 6
- 230000004988 N-glycosylation Effects 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 6
- 238000004113 cell culture Methods 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 229960001388 interferon-beta Drugs 0.000 claims 6
- 239000002609 medium Substances 0.000 claims 6
- 235000015097 nutrients Nutrition 0.000 claims 6
- 229920001542 oligosaccharide Polymers 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 4
- 238000001042 affinity chromatography Methods 0.000 claims 4
- 239000012539 chromatography resin Substances 0.000 claims 4
- 238000007865 diluting Methods 0.000 claims 4
- 239000013024 dilution buffer Substances 0.000 claims 4
- 239000012636 effector Substances 0.000 claims 4
- 150000002482 oligosaccharides Chemical class 0.000 claims 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 4
- 229920000053 polysorbate 80 Polymers 0.000 claims 4
- 229940068968 polysorbate 80 Drugs 0.000 claims 4
- 239000011347 resin Substances 0.000 claims 4
- 229920005989 resin Polymers 0.000 claims 4
- 238000001542 size-exclusion chromatography Methods 0.000 claims 4
- 239000001509 sodium citrate Substances 0.000 claims 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 239000007640 basal medium Substances 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 238000011012 sanitization Methods 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 238000003860 storage Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 238000010790 dilution Methods 0.000 claims 2
- 239000012895 dilution Substances 0.000 claims 2
- 239000012149 elution buffer Substances 0.000 claims 2
- 239000006167 equilibration buffer Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 238000009097 single-agent therapy Methods 0.000 claims 2
- 229940074404 sodium succinate Drugs 0.000 claims 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 2
- MDYOLVRUBBJPFM-UHFFFAOYSA-N tropolone Chemical compound OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 claims 2
- 238000000108 ultra-filtration Methods 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- 238000003989 weak cation exchange chromatography Methods 0.000 claims 2
- 239000012608 weak cation exchange resin Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 238000005277 cation exchange chromatography Methods 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 239000000356 contaminant Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 1
- 235000011152 sodium sulphate Nutrition 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 238000002305 strong-anion-exchange chromatography Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000011534 wash buffer Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490998P | 2011-05-27 | 2011-05-27 | |
| US61/490,998 | 2011-05-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012121876A Division RU2661764C2 (ru) | 2011-05-27 | 2012-05-25 | Композиции и способы на основе dac hyp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018119112A true RU2018119112A (ru) | 2018-11-07 |
Family
ID=46177353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018119112A RU2018119112A (ru) | 2011-05-27 | 2012-05-25 | Композиции и способы на основе dac hyp |
| RU2012121876A RU2661764C2 (ru) | 2011-05-27 | 2012-05-25 | Композиции и способы на основе dac hyp |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012121876A RU2661764C2 (ru) | 2011-05-27 | 2012-05-25 | Композиции и способы на основе dac hyp |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US20120301429A1 (enExample) |
| EP (1) | EP2527429A3 (enExample) |
| JP (4) | JP6055615B2 (enExample) |
| CN (2) | CN107090040A (enExample) |
| AU (4) | AU2012203095B2 (enExample) |
| BR (1) | BR102012012673A8 (enExample) |
| CA (1) | CA2777978A1 (enExample) |
| MX (1) | MX339533B (enExample) |
| RU (2) | RU2018119112A (enExample) |
| SG (1) | SG185920A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102012012673A8 (pt) * | 2011-05-27 | 2021-02-17 | Abbott Biotherapeutics Corp | célula ns0 modificada, métodos de produzir uma proteína recombinante, de obter uma célula hospedeira de mamífero, de sanitizar uma coluna de cromatografia com afinidade para proteína a e de tratar um paciente sofrendo de esclerose múltipla, vetor, composição, processos para colher uma proteína recombinante de uma cultura de célula e para produzir uma composição purificada de daclizumab, meios, e, tampão |
| WO2013022972A1 (en) | 2011-08-08 | 2013-02-14 | Abbott Biotherapeutics Corporation | Methods of treating progressive forms of multiple sclerosis |
| CA2857298A1 (en) * | 2011-11-30 | 2013-06-06 | Abbvie Biotherapeutics Inc. | Vectors and host cells comprising a modified sv40 promoter for protein expression |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US11014129B2 (en) | 2013-09-04 | 2021-05-25 | Emd Millipore Corporation | Methods of cleaning a protein A based affinity chromatography column |
| GB201503578D0 (en) * | 2015-03-03 | 2015-04-15 | Ge Healthcare Bio Sciences Ab | Sanitization method for affinity chromatography matrices |
| EP3274359B1 (en) | 2015-03-23 | 2022-11-02 | Alexion Pharmaceuticals, Inc. | Virus filtration |
| PT3334760T (pt) | 2015-08-12 | 2021-04-23 | Pfizer | Cisteínas de anticorpos com cap e sem cap e utilizações das mesmas na conjugação de anticorpo-fármaco |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| US11028410B2 (en) | 2016-01-27 | 2021-06-08 | Just-Evotec Biologics, Inc. | Hybrid promoter and uses thereof |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| WO2018027195A1 (en) * | 2016-08-05 | 2018-02-08 | Abbvie Biotherapeutics Inc. | Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same |
| KR20240152951A (ko) * | 2017-01-30 | 2024-10-22 | 리제너론 파마슈티칼스 인코포레이티드 | 크로마토그래피에서 바이오버든을 감소시키기 위한 조성물 및 방법 |
| EP3728288B1 (en) * | 2017-12-21 | 2022-01-19 | Genzyme Corporation | Methods for enhanced removal of impurities during protein a chromatography |
| JP7739181B2 (ja) * | 2019-04-17 | 2025-09-16 | ブリストル－マイヤーズ スクイブ カンパニー | クロマトグラフィー樹脂の再生方法 |
| KR102731889B1 (ko) * | 2019-07-18 | 2024-11-19 | 에이비온 주식회사 | 2당화된 인터페론-베타 단백질의 정제 방법 |
| MX2022001166A (es) * | 2019-08-01 | 2022-02-23 | Regeneron Pharma | Metodo para inactivacion viral. |
| MY190623A (en) | 2019-12-06 | 2022-04-27 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| CN115803009A (zh) | 2020-05-08 | 2023-03-14 | 瑞泽恩制药公司 | 用于治疗眼病和癌症的vegf阱和微阱及方法 |
| JP7631742B2 (ja) * | 2020-11-10 | 2025-02-19 | 東ソー株式会社 | ペプチド性リガンド固定化カラムの洗浄方法 |
| MX2023012903A (es) * | 2021-05-03 | 2023-11-08 | Boehringer Ingelheim Int | Metodo para producir spesolimab. |
| CN114181300A (zh) * | 2021-12-20 | 2022-03-15 | 方坦思(上海)生物医药有限公司 | 一种高纯度单克隆抗体的制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1430566A (en) * | 1974-11-15 | 1976-03-31 | Nestel Sa | Isolation of proteins |
| US7442777B2 (en) * | 2000-11-29 | 2008-10-28 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| RU2318537C2 (ru) * | 2001-04-06 | 2008-03-10 | Юниверсити Оф Бристоль | Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам |
| JP2005325133A (ja) * | 2001-10-15 | 2005-11-24 | Kirin Brewery Co Ltd | 抗ｈｌａ−ｄｒ抗体の利用 |
| US20040002135A1 (en) * | 2002-03-28 | 2004-01-01 | Sauer Paul W. | Adapted NS0 cell lines with the ability to grow under glutamine-free conditions |
| US7365168B2 (en) * | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1614693A4 (en) * | 2003-03-31 | 2006-07-19 | Kirin Brewery | Purification of a human monoclonal antibody and human polyclonal antibody |
| US20070190057A1 (en) * | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
| WO2007146847A2 (en) | 2006-06-09 | 2007-12-21 | University Of Maryland, Baltimore | Glycosylation engineered antibody therapy |
| JP2010510963A (ja) * | 2006-06-14 | 2010-04-08 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | セラミックヒドロキシアパタイトを使用する抗体の精製方法 |
| US20090209656A1 (en) * | 2006-07-06 | 2009-08-20 | Ge Healthcare Bio-Sciences Ab | Disinfection/sanitation method where the material is treated with a solution comprising benzyl alcohol and c2-3 alcohol |
| US20110003338A1 (en) * | 2008-03-11 | 2011-01-06 | Robert Bayer | Antibodies with enhanced adcc function |
| US20100055098A1 (en) * | 2008-08-28 | 2010-03-04 | Facet Biotech Corporation | Method for treating multiple sclerosis patients with anti-il2r antibodies |
| WO2010138502A2 (en) * | 2009-05-26 | 2010-12-02 | Momenta Pharmaceuticals, Inc. | Production of glycoproteins |
| AU2010256455A1 (en) | 2009-06-05 | 2012-01-19 | Momenta Pharmaceuticals, Inc. | Methods of modulating fucosylation of glycoproteins |
| SG177577A1 (en) * | 2009-08-07 | 2012-03-29 | Emd Millipore Corp | Methods for purifying a target protein from one or more impurities in a sample |
| US20110053223A1 (en) | 2009-08-14 | 2011-03-03 | Robert Bayer | Cell culture methods to make antibodies with enhanced adcc function |
| US10087236B2 (en) * | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| IL323000A (en) | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| BR102012012673A8 (pt) | 2011-05-27 | 2021-02-17 | Abbott Biotherapeutics Corp | célula ns0 modificada, métodos de produzir uma proteína recombinante, de obter uma célula hospedeira de mamífero, de sanitizar uma coluna de cromatografia com afinidade para proteína a e de tratar um paciente sofrendo de esclerose múltipla, vetor, composição, processos para colher uma proteína recombinante de uma cultura de célula e para produzir uma composição purificada de daclizumab, meios, e, tampão |
-
2012
- 2012-05-25 BR BR102012012673A patent/BR102012012673A8/pt not_active Application Discontinuation
- 2012-05-25 MX MX2012006115A patent/MX339533B/es active IP Right Grant
- 2012-05-25 CN CN201710204584.8A patent/CN107090040A/zh active Pending
- 2012-05-25 CA CA2777978A patent/CA2777978A1/en not_active Abandoned
- 2012-05-25 RU RU2018119112A patent/RU2018119112A/ru not_active Application Discontinuation
- 2012-05-25 CN CN2012102472614A patent/CN102796705A/zh active Pending
- 2012-05-25 SG SG2012038774A patent/SG185920A1/en unknown
- 2012-05-25 RU RU2012121876A patent/RU2661764C2/ru active
- 2012-05-25 EP EP12169595.1A patent/EP2527429A3/en not_active Withdrawn
- 2012-05-25 JP JP2012119327A patent/JP6055615B2/ja not_active Expired - Fee Related
- 2012-05-25 AU AU2012203095A patent/AU2012203095B2/en not_active Ceased
- 2012-05-25 US US13/481,081 patent/US20120301429A1/en not_active Abandoned
-
2015
- 2015-01-21 US US14/601,909 patent/US9676860B2/en not_active Expired - Fee Related
- 2015-03-27 US US14/671,653 patent/US9340619B2/en not_active Expired - Fee Related
- 2015-06-09 US US14/735,062 patent/US9260528B2/en not_active Expired - Fee Related
-
2016
- 2016-05-04 AU AU2016202873A patent/AU2016202873B2/en not_active Ceased
- 2016-08-22 JP JP2016161679A patent/JP2016210796A/ja active Pending
-
2017
- 2017-05-04 US US15/587,127 patent/US9815903B2/en not_active Expired - Fee Related
- 2017-10-04 US US15/724,443 patent/US20180127506A1/en not_active Abandoned
-
2018
- 2018-01-29 AU AU2018200654A patent/AU2018200654A1/en not_active Abandoned
- 2018-04-05 JP JP2018073025A patent/JP2018134091A/ja active Pending
-
2020
- 2020-01-31 US US16/779,336 patent/US20200157230A1/en not_active Abandoned
- 2020-03-02 JP JP2020034673A patent/JP2020078348A/ja not_active Withdrawn
- 2020-03-31 AU AU2020202298A patent/AU2020202298A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018119112A (ru) | Композиции и способы на основе dac hyp | |
| JP2012244993A5 (enExample) | ||
| KR100496356B1 (ko) | 포유동물세포배양으로생산되는단백질의시알릴화조절방법 | |
| FI110002B (fi) | Menetelmä puhdistetun IgG-vasta-ainevalmisteen saamiseksi | |
| EP3400241B1 (en) | Modulation of afucosylated species in a monoclonal antibody composition | |
| US20130089540A1 (en) | New Humanized Anti-CD20 Monoclonal Antibody | |
| US20190048070A1 (en) | Reduction of high molecular weight species, acidic charge species and fragments in a monoclonal antibody composition | |
| US20090060904A1 (en) | Vegetarian Protein A Preparation and Methods Thereof | |
| EP3101035B1 (en) | Bifunctional fusion protein, preparation method therefor, and use thereof | |
| CN107208081B (zh) | 用于从包含污染宿主细胞蛋白质的材料纯化重组人α-半乳糖苷酶A的方法 | |
| AU2006292700A1 (en) | Protein a production and purification without using animal derived components | |
| EP4335459A1 (en) | Pharmaceutical composition for treatment of mucopolysaccharidosis type 1 | |
| US20240209115A1 (en) | Methods for reducing low molecular weight species of recombinantly-produced proteins | |
| KR100708403B1 (ko) | 항혈전 항체의 정제방법 | |
| CA3246548A1 (en) | Immunoconjugate preparation IL2 | |
| HK1178205A (en) | Dac hyp compositions and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20210525 |